Cyprotex

Investment date September 2013
Exit date December 2016
Sector Life sciences
Deal type PIPE
Exit type Trade sale
Total investment £7.8 million
Realised proceeds £22.8 million

Investment overview

Cyprotex was a contract research organisation specialising in in-vitro and in-silico ADME-tox testing. It was a leading outsource provider of such services to the pharmaceutical industry. It also provided in-vitro toxicity testing to the cosmetics and agrochemical industries; and had laboratories in both the UK and the US.